No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(11c)pe2i |
- |
- |
- |
- |
1件: 6 |
2 |
(2-chloro-5-[11c]methoxy-n-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) |
- |
- |
- |
- |
1件: 6 |
3 |
(3beta, 5beta, 25r)-spirostan-3-ol |
- |
- |
- |
- |
1件: 6 |
4 |
(3ß, 5ß, 25r)-spirostan-3-ol |
- |
- |
- |
- |
1件: 6 |
5 |
(6s)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol |
- |
- |
- |
- |
1件: 6 |
6 |
(r)-troloxamide quinone |
- |
- |
- |
- |
1件: 6 |
7 |
(s)- 2- amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol |
- |
- |
- |
- |
1件: 6 |
8 |
(s)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate |
- |
- |
- |
- |
1件: 6 |
9 |
0 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
10 |
0.3 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
11 |
0.9% sodium chloride |
Sodium chloride |
D02056 |
- |
- |
3件: 6, 14, 51 |
12 |
0.9% sodium chloride (normal saline) |
Sodium chloride |
D02056 |
- |
- |
1件: 6 |
13 |
009-0 |
- |
- |
- |
- |
1件: 6 |
14 |
009-1 |
- |
- |
- |
- |
1件: 6 |
15 |
009-2 |
- |
- |
- |
- |
1件: 6 |
16 |
009-3 |
- |
- |
- |
- |
1件: 6 |
17 |
009-4 |
- |
- |
- |
- |
1件: 6 |
18 |
009-5 |
- |
- |
- |
- |
1件: 6 |
19 |
009-a0 |
- |
- |
- |
- |
1件: 6 |
20 |
009-a1 |
- |
- |
- |
- |
1件: 6 |
21 |
009-a2 |
- |
- |
- |
- |
1件: 6 |
22 |
009-a3 |
- |
- |
- |
- |
1件: 6 |
23 |
1 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
24 |
1 mg qd to 7 mg qd pf-06649751 (if de-escalated in parent study) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
25 |
1 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
26 |
1. tesofensine (ns 2330) |
Tesofensine |
- |
- |
- |
1件: 6 |
27 |
1.0 mg rasagiline mesylate |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
28 |
11c-pbr28 |
- |
- |
- |
- |
1件: 6 |
29 |
11c-raclopride |
Raclopride |
- |
- |
- |
1件: 6 |
30 |
15 mg qd de-escalated to 7 mg qd pf-06649751 in parent study remain at 7 mg qd |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
31 |
15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
32 |
15o h2o |
- |
- |
- |
- |
1件: 6 |
33 |
18-fdtbz |
- |
- |
- |
- |
1件: 6 |
34 |
18f florbetaben |
- |
- |
- |
- |
1件: 6 |
35 |
18f- dtbz |
- |
- |
- |
- |
1件: 6 |
36 |
18f-av-133 |
Florbenazine f-18 |
- |
- |
- |
1件: 6 |
37 |
18f-av-45 |
- |
- |
- |
- |
2件: 6, 127 |
38 |
18f-dopa |
- |
- |
- |
- |
2件: 6, 75 |
39 |
18f-dopa pet |
- |
- |
- |
- |
1件: 6 |
40 |
18f-dtbz |
- |
- |
- |
- |
1件: 6 |
41 |
18f-dtbz av-133 |
- |
- |
- |
- |
1件: 6 |
42 |
18f-fdg |
Fludeoxyglucose f-18 |
- |
- |
- |
7件: 6, 13, 46, 53, 84, 127, 300 |
43 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
1件: 6 |
44 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
1件: 6 |
45 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
1件: 6 |
46 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
1件: 6 |
47 |
2 mg perampanel |
Perampanel |
D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 6 |
48 |
200 mg bia 6-512 |
- |
- |
- |
- |
1件: 6 |
49 |
207-3120 |
- |
- |
- |
- |
1件: 6 |
50 |
240mg amantadine hcl er tablets |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
51 |
25330 |
- |
- |
- |
- |
1件: 6 |
52 |
3 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
53 |
3 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
54 |
3 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
55 |
3- (9,10- didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate |
- |
- |
- |
- |
1件: 6 |
56 |
320mg amantadine hcl er tablets |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
57 |
4 mg perampanel |
Perampanel |
D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 6 |
58 |
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
59 |
6aß - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
60 |
7 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
61 |
7 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
62 |
7-beta-hydroxyepiandrosterone |
- |
- |
- |
- |
1件: 6 |
63 |
[11c]pbr28 |
- |
- |
- |
- |
1件: 6 |
64 |
[11c]pxt012253 |
- |
- |
- |
- |
1件: 6 |
65 |
[11c]smw139 |
- |
- |
- |
- |
1件: 6 |
66 |
[123i] 5-ia |
- |
- |
- |
- |
1件: 6 |
67 |
[123i] ibvm and spect imaging |
- |
- |
- |
- |
1件: 6 |
68 |
[123i] mzint injection and serial dynamic spect imaging |
- |
- |
- |
- |
1件: 6 |
69 |
[123i]-ibvm |
- |
- |
- |
- |
1件: 6 |
70 |
[123i]b-cit |
- |
- |
- |
- |
1件: 6 |
71 |
[123i]b-cit spect imaging |
- |
- |
- |
- |
1件: 6 |
72 |
[123i]beta cit |
- |
- |
- |
- |
1件: 6 |
73 |
[123i]beta cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
74 |
[123i]beta-cit |
- |
- |
- |
- |
1件: 6 |
75 |
[123i]beta-cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
76 |
[123i]clinde |
- |
- |
- |
- |
2件: 6, 13 |
77 |
[123i]mni-420 |
- |
- |
- |
- |
2件: 6, 8 |
78 |
[123i]ß cit |
- |
- |
- |
- |
1件: 6 |
79 |
[123i]ß cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
80 |
[123i]ß-cit |
- |
- |
- |
- |
1件: 6 |
81 |
[123i]ß-cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
82 |
[14c]-bia 9-1067 |
- |
- |
- |
- |
1件: 6 |
83 |
[15o]h2o |
- |
- |
- |
- |
1件: 6 |
84 |
[18f] cfpypb |
- |
- |
- |
- |
1件: 6 |
85 |
[18f] lbt-999 pet |
- |
- |
- |
- |
1件: 6 |
86 |
[18f] pbr06 |
- |
- |
- |
- |
2件: 6, 13 |
87 |
[18f]-(e)-n-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane |
- |
- |
- |
- |
1件: 6 |
88 |
[18f]-feppa |
- |
- |
- |
- |
2件: 6, 13 |
89 |
[18f]dpa-714 pet scan |
- |
- |
- |
- |
1件: 6 |
90 |
[18f]fdopa pet/ct |
- |
- |
- |
- |
1件: 6 |
91 |
[18f]fe-pe2i |
- |
- |
- |
- |
1件: 6 |
92 |
[18f]fpeb |
- |
- |
- |
- |
3件: 6, 8, 206 |
93 |
[18f]mk-9470 |
- |
- |
- |
- |
1件: 6 |
94 |
[18f]mni-1126 |
- |
- |
- |
- |
1件: 6 |
95 |
[18f]mppf |
- |
- |
- |
- |
1件: 6 |
96 |
[18f]nos |
- |
- |
- |
- |
1件: 6 |
97 |
[18f]p17-059 |
- |
- |
- |
- |
1件: 6 |
98 |
[18f]t807 ([18f]mni-777) |
- |
- |
- |
- |
2件: 5, 6 |
99 |
Ab1010 |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
100 |
Abbv-0805 |
- |
- |
- |
- |
1件: 6 |
101 |
Abbv-951 |
- |
- |
- |
- |
1件: 6 |
102 |
Abt-slv187 |
- |
- |
- |
- |
1件: 6 |
103 |
Acamprosate |
Acamprosate |
D02780, D07058 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 6, 206 |
104 |
Accordion pill carbidopa/levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
105 |
Accordion pill™ carbidopa/levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
106 |
Accordion pill™ carbidopa/levodopa 50/400 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
107 |
Accordion pill™ carbidopa/levodopa 50/500 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
108 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
109 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
110 |
Acp-103 |
- |
- |
- |
- |
1件: 6 |
111 |
Acr325 |
Acr325 |
- |
- |
- |
1件: 6 |
112 |
Active comparator |
- |
- |
- |
- |
2件: 6, 46 |
113 |
Active drug (biib014) at 10, 30, 100, or 300 mg once daily. |
Dihydrotachysterol |
D00299 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 6 |
114 |
Active drug: pimavanserin 17mg (2 strength tablets) |
Pimavanserin |
- |
- |
- |
1件: 6 |
115 |
Active investigational treatment ent-01 |
- |
- |
- |
- |
1件: 6 |
116 |
Ad-810n (zonisamide) |
Zonisamide |
D00538 |
8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
1件: 6 |
117 |
Adjuvant without active component |
- |
- |
- |
- |
2件: 6, 17 |
118 |
Administration of stable isotope-labelled leucine- |
L-leucine |
D00030 |
- |
- |
1件: 6 |
119 |
Ads-5102 |
- |
- |
- |
- |
2件: 6, 13 |
120 |
Ads-5102 (extended release amantadine hcl) |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
121 |
Adx48621 |
- |
- |
- |
- |
1件: 6 |
122 |
Affitope® pd01a |
- |
- |
- |
- |
1件: 6 |
123 |
Affitope® pd01a + adjuvant |
- |
- |
- |
- |
2件: 6, 17 |
124 |
Afq056 |
- |
- |
- |
- |
3件: 6, 8, 206 |
125 |
Afq056 with l-dopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
126 |
Agomelatine |
Agomelatine |
D02578 |
3件: HTR2C, MTNR1A, MTNR1B |
6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
1件: 6 |
127 |
Agomelatine or piacebo |
Agomelatine |
D02578 |
3件: HTR2C, MTNR1A, MTNR1B |
6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
1件: 6 |
128 |
Allogeneic bone marrow-derived mscs |
- |
- |
- |
- |
1件: 6 |
129 |
Allopurinol |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
6件: 6, 46, 57, 66, 96, 97 |
130 |
Altropane |
Altropane |
- |
- |
- |
1件: 6 |
131 |
Altropane® |
- |
- |
- |
- |
1件: 6 |
132 |
Amantadine |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
133 |
Amantadine 300 mg |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
134 |
Amantadine hcl er |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
135 |
Amantadine hcl extended release |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
136 |
Amantadine hydrochloride |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
137 |
Amantadine sulfate |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
138 |
Ambrosan 60mg tablets |
- |
- |
- |
- |
1件: 6 |
139 |
Ambroxol |
Ambroxol |
D07442 |
- |
- |
2件: 6, 19 |
140 |
Ambroxol hydrochloride |
Ambroxol |
D07442 |
- |
- |
1件: 6 |
141 |
Amoxicillin |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
6件: 6, 46, 63, 96, 97, 222 |
142 |
Ampyra first, |
- |
- |
- |
- |
1件: 6 |
143 |
Anavex2-73 |
- |
- |
- |
- |
2件: 6, 156 |
144 |
Anti-parkinson medication |
- |
- |
- |
- |
4件: 5, 6, 7, 17 |
145 |
Ap-cd/ld |
- |
- |
- |
- |
1件: 6 |
146 |
Ap09004 |
- |
- |
- |
- |
1件: 6 |
147 |
Apl-130277 |
- |
- |
- |
- |
1件: 6 |
148 |
Aplindore |
Aplindore |
- |
- |
- |
1件: 6 |
149 |
Aplindore mr tablets |
Aplindore |
- |
- |
- |
1件: 6 |
150 |
Apo-go |
- |
- |
- |
- |
1件: 6 |
151 |
Apo-go® |
- |
- |
- |
- |
1件: 6 |
152 |
Apokinon |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
153 |
Apokyn |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
154 |
Apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
155 |
Apomorphine 0.25% (2.5mg/ml) |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
156 |
Apomorphine hcl injection |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
157 |
Apomorphine hydrochloride |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
158 |
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
159 |
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
160 |
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
161 |
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
162 |
Apomorphine hydrocloride |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
163 |
Apomorphine hydrocloride hemihydrate |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
164 |
Apomorphine infusion |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
165 |
Apomorphine nasal powder |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
166 |
Aqw051 |
- |
- |
- |
- |
1件: 6 |
167 |
Aricept |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
4件: 6, 13, 78, 124 |
168 |
Aricept 5 mg-filmtabletten |
- |
- |
- |
- |
1件: 6 |
169 |
Aricept 5mg-filmtabletten |
- |
- |
- |
- |
1件: 6 |
170 |
Aripiprazole |
Aripiprazole |
D01164 |
4件: DRD2, DRD3, HTR1A, HTR2A |
12件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 206 |
171 |
Armodafinil |
Armodafinil |
D03215 |
1件: SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
3件: 6, 13, 84 |
172 |
At 10 |
Dihydrotachysterol |
D00299 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 6 |
173 |
Atm fog in pd |
- |
- |
- |
- |
1件: 6 |
174 |
Atomoxetine |
Atomoxetine |
D02574, D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
175 |
Atypical antipsychotics |
- |
- |
- |
- |
1件: 6 |
176 |
Autologous mesenchymal stem cells |
- |
- |
- |
- |
5件: 2, 6, 13, 17, 46 |
177 |
Av-101 |
- |
- |
- |
- |
1件: 6 |
178 |
Avalox |
Moxifloxacin |
D00874, D08237 |
- |
- |
1件: 6 |
179 |
Avalox - 400 mg compresse rivestite con film 5 compresse in blister pp/al |
Moxifloxacin |
D00874, D08237 |
- |
- |
1件: 6 |
180 |
Ave8112 |
- |
- |
- |
- |
1件: 6 |
181 |
Avp-923 |
- |
- |
- |
- |
3件: 2, 6, 13 |
182 |
Avp-923-45 |
- |
- |
- |
- |
1件: 6 |
183 |
Azd3241 |
- |
- |
- |
- |
2件: 6, 17 |
184 |
Azd3241 300 mg bid |
- |
- |
- |
- |
1件: 6 |
185 |
Azd3241 600 mg bid |
- |
- |
- |
- |
1件: 6 |
186 |
Azd3241 alternative titration scheme with formulation 1 or 2 |
- |
- |
- |
- |
1件: 6 |
187 |
Azd3241 er formulation 1 |
- |
- |
- |
- |
1件: 6 |
188 |
Azd3241 extended release tablets 100 mg |
- |
- |
- |
- |
1件: 6 |
189 |
Azd3241 extended release tablets 25 mg |
- |
- |
- |
- |
1件: 6 |
190 |
Azilect |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
3件: 5, 6, 17 |
191 |
Azilect® |
- |
- |
- |
- |
1件: 6 |
192 |
B-cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
193 |
B6, b12, l-methylfolate |
Levomefolic acid |
D09353 |
- |
- |
1件: 6 |
194 |
Balance |
Isoxaflutole |
- |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
195 |
Bavisant |
Bavisant |
D09870 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
196 |
Bavisant dihydrochloride monohydrate |
Bavisant |
D09870 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
197 |
Bavisant hydrochloride monohydrate |
Bavisant |
D09870 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
198 |
Bee venom |
- |
- |
- |
- |
1件: 6 |
199 |
Ben-2001 |
- |
- |
- |
- |
1件: 6 |
200 |
Benserazide |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
201 |
Benserazide hydrochloride |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
202 |
Benzofuran |
Benzofuran |
- |
- |
- |
1件: 6 |
203 |
Best medical treatment |
- |
- |
- |
- |
1件: 6 |
204 |
Bf 2.649 |
- |
- |
- |
- |
1件: 6 |
205 |
Bf2.649 |
- |
- |
- |
- |
1件: 6 |
206 |
Bf2.649 (pitolisant) |
Pitolisant |
D10749 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
207 |
Bi-sifrol® |
- |
- |
- |
- |
1件: 6 |
208 |
Bia 3-202 |
- |
- |
- |
- |
1件: 6 |
209 |
Bia 3-202 (200 mg) |
- |
- |
- |
- |
1件: 6 |
210 |
Bia 6-512 |
- |
- |
- |
- |
1件: 6 |
211 |
Bia 6-512 100 mg |
- |
- |
- |
- |
1件: 6 |
212 |
Bia 6-512 100 mg dose |
- |
- |
- |
- |
1件: 6 |
213 |
Bia 6-512 200 mg dose |
- |
- |
- |
- |
1件: 6 |
214 |
Bia 6-512 25 mg |
- |
- |
- |
- |
1件: 6 |
215 |
Bia 6-512 25 mg dose |
- |
- |
- |
- |
1件: 6 |
216 |
Bia 6-512 400 mg |
- |
- |
- |
- |
1件: 6 |
217 |
Bia 6-512 50 mg dose |
- |
- |
- |
- |
1件: 6 |
218 |
Bia 9-1067 |
- |
- |
- |
- |
1件: 6 |
219 |
Bia 9-1067 (test) |
- |
- |
- |
- |
1件: 6 |
220 |
Bia 9-1067 15 mg |
- |
- |
- |
- |
1件: 6 |
221 |
Bia 9-1067 25 mg |
- |
- |
- |
- |
1件: 6 |
222 |
Bia 9-1067 30 mg |
- |
- |
- |
- |
1件: 6 |
223 |
Bia 9-1067 5 mg |
- |
- |
- |
- |
1件: 6 |
224 |
Bia 9-1067 micronized |
- |
- |
- |
- |
1件: 6 |
225 |
Bia 9-1067 non-micronized |
- |
- |
- |
- |
1件: 6 |
226 |
Biib014 |
- |
- |
- |
- |
1件: 6 |
227 |
Biib054 |
- |
- |
- |
- |
1件: 6 |
228 |
Biib094 |
- |
- |
- |
- |
1件: 6 |
229 |
Bisphosphonates |
- |
- |
- |
- |
2件: 6, 274 |
230 |
Bone marrow derived mesenchymal stem cells |
- |
- |
- |
- |
2件: 6, 60 |
231 |
Bont-a |
- |
- |
- |
- |
1件: 6 |
232 |
Botox |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
4件: 6, 13, 149, 226 |
233 |
Botulinum toxin |
- |
- |
- |
- |
1件: 6 |
234 |
Botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
235 |
Botulinum toxin type b |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
3件: 2, 6, 51 |
236 |
Botulinum toxin type b (myobloc) |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
2件: 2, 6 |
237 |
Botulinum toxin: xeomin |
- |
- |
- |
- |
1件: 6 |
238 |
Bromocriptine |
Bromocriptine |
D00780, D03165 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 74 |
239 |
Bromocriptine and other dopamine agonists |
Bromocriptine |
D00780, D03165 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
240 |
Btrx-246040 |
- |
- |
- |
- |
1件: 6 |
241 |
Btx-a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 6 |
242 |
Bumetanide |
Bumetanide |
D00247 |
1件: SLC12A2 |
3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
2件: 6, 158 |
243 |
Bumetanide white, oblong, scored tablet |
Bumetanide |
D00247 |
1件: SLC12A2 |
3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
1件: 6 |
244 |
Bupleurum+ginkgo |
Ginkgo biloba |
- |
- |
- |
1件: 6 |
245 |
Buspirone |
Buspirone |
D00702, D07593 |
2件: DRD2, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 51 |
246 |
Buspirone hydrochloride |
Buspirone |
D00702, D07593 |
2件: DRD2, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 6 |
247 |
Butylphthalide |
Butylphthalide |
- |
- |
- |
2件: 2, 6 |
248 |
Byetta 5 micrograms |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
249 |
Cabaseril |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
250 |
Cabaseril, 1,0 mg tablette |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
251 |
Cabaseril, 2,0 mg tablette |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
252 |
Cabergoline |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 74, 75 |
253 |
Caffeine |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 2, 6, 46, 78, 96, 97 |
254 |
Caffeine 100-200 mg bid |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
255 |
Caffeine alkaloid |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
256 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
257 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
258 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
259 |
Cannabis oil |
Medical cannabis |
- |
- |
- |
1件: 6 |
260 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
261 |
Capsaicin |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
6件: 2, 6, 19, 86, 113, 226 |
262 |
Capsaicin vapor |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 6 |
263 |
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
264 |
Capture |
Bifenthrin |
- |
- |
- |
2件: 6, 46 |
265 |
Carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
266 |
Carbidopa 20 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
267 |
Carbidopa 27.5 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
268 |
Carbidopa 65 mg capsule |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
269 |
Carbidopa and levodopa 25mg/100mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
270 |
Carbidopa fu |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
271 |
Carbidopa levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
272 |
Carbidopa monohydrate |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
273 |
Carbidopa, levodopa, entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
274 |
Carbidopa- levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
275 |
Carbidopa-levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
3件: 2, 4, 6 |
276 |
Carbidopa/l-dopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
277 |
Carbidopa/l-dopa/entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
278 |
Carbidopa/levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
279 |
Carbidopa/levodopa, immediate release |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
280 |
Carbidopa/levodopa/entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
281 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
7件: 6, 46, 85, 86, 96, 97, 298 |
282 |
Carnosine |
Carnosine |
- |
- |
- |
2件: 6, 13 |
283 |
Carnosine supplementation |
Carnosine |
- |
- |
- |
1件: 6 |
284 |
Carvedilol |
Carvedilol |
D00255, D03415 |
5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 |
12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 6, 57, 86, 113 |
285 |
Catapres ampoules |
Clonidine |
D00281, D00604 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 6 |
286 |
Cd-ld cr |
- |
- |
- |
- |
1件: 6 |
287 |
Cd-ld ir |
- |
- |
- |
- |
1件: 6 |
288 |
Cdnf |
- |
- |
- |
- |
1件: 6 |
289 |
Ceftriaxone |
Ceftriaxone |
D00924, D07659 |
- |
- |
3件: 2, 6, 97 |
290 |
Cep-1347 |
- |
- |
- |
- |
1件: 6 |
291 |
Cep-1347 10mg |
- |
- |
- |
- |
1件: 6 |
292 |
Cep-1347 50mg |
- |
- |
- |
- |
1件: 6 |
293 |
Cep1347 |
Cep1347 |
- |
- |
- |
1件: 6 |
294 |
Cep1347 25mg |
Cep1347 |
- |
- |
- |
1件: 6 |
295 |
Cere-120 |
- |
- |
- |
- |
1件: 6 |
296 |
Cere-120: adeno-associated virus delivery of neurturin |
- |
- |
- |
- |
1件: 6 |
297 |
Cerebral dopamine neurotrophic factor |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
298 |
Ceretec |
Technetium tc-99m exametazime |
D02284 |
- |
- |
1件: 6 |
299 |
Ceretec (tm) estabilizado |
Technetium tc-99m exametazime |
D02284 |
- |
- |
1件: 6 |
300 |
Champix |
Varenicline |
D08669 |
2件: CHRNA4, CHRNB2 |
3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
301 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
302 |
Chocolate |
Cocoa |
- |
- |
- |
1件: 6 |
303 |
Cipralex |
- |
- |
- |
- |
1件: 6 |
304 |
Cjh1 (clr4001) |
- |
- |
- |
- |
1件: 6 |
305 |
Clarithromycin |
Clarithromycin |
D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
306 |
Clarium |
Loratadine |
D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 6 |
307 |
Clarium 50 mg retardtabletten |
Loratadine |
D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 6 |
308 |
Clartihromycin, amoxicillin, and omeprazole |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
1件: 6 |
309 |
Clonazepam |
Clonazepam |
D00280 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
310 |
Clonidine |
Clonidine |
D00281, D00604 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 6, 78 |
311 |
Clonidine hydrochloride |
Clonidine |
D00281, D00604 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 6, 78 |
312 |
Clozapine |
Clozapine |
D00283 |
11件: ADRA2A, ADRA2B, ADRA2C, DRD4, HTR2A, HTR2C, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
8件: Calcium signaling pathway, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cGMP-PKG signaling pathway |
1件: 6 |
313 |
Cocoa |
Cocoa |
- |
- |
- |
1件: 6 |
314 |
Coenzyme q10 |
Ubidecarenone |
D01065 |
- |
- |
10件: 2, 6, 8, 10, 46, 57, 113, 193, 214, 215 |
315 |
Coenzyme q10 nanodispersion (nanoquinone) |
Ubidecarenone |
D01065 |
- |
- |
1件: 6 |
316 |
Coenzyme q10 with vitamin e |
Vitamin e |
D02331 |
- |
- |
1件: 6 |
317 |
Cogane™ (pym50028) |
- |
- |
- |
- |
1件: 6 |
318 |
Cohort 1:nilotinib oral capsules (150mg or 300mg) |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 6 |
319 |
Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1) |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 6 |
320 |
Combination injection of epo and g-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 6 |
321 |
Comparator: carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
322 |
Comparator: levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
323 |
Comtan |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
324 |
Comtan® |
- |
- |
- |
- |
1件: 6 |
325 |
Comtess |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
326 |
Comtess® |
- |
- |
- |
- |
1件: 6 |
327 |
Continuous intrajejunal infusion of levodopa-carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
328 |
Continuous release dopamine agonists |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
329 |
Control |
Chloroxylenol |
D03473 |
- |
- |
4件: 6, 13, 46, 168 |
330 |
Controlled-release levodopa / carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
331 |
Coq10 |
Ubidecarenone |
D01065 |
- |
- |
3件: 5, 6, 8 |
332 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
333 |
Cu(ii)atsm |
- |
- |
- |
- |
2件: 2, 6 |
334 |
Cvd00118-e |
- |
- |
- |
- |
1件: 6 |
335 |
Cvt-301 |
- |
- |
- |
- |
1件: 6 |
336 |
Cvt-301 (dose level 1) |
- |
- |
- |
- |
1件: 6 |
337 |
Cvt-301 (dose level 2) |
- |
- |
- |
- |
1件: 6 |
338 |
Cvt-301 35mg |
- |
- |
- |
- |
1件: 6 |
339 |
Cvt-301 50mg |
- |
- |
- |
- |
1件: 6 |
340 |
Cvt-301 high dose |
- |
- |
- |
- |
1件: 6 |
341 |
Cvt-301 low dose |
- |
- |
- |
- |
1件: 6 |
342 |
Cvt-301, lip |
- |
- |
- |
- |
1件: 6 |
343 |
Cvxl-0107 |
- |
- |
- |
- |
1件: 6 |
344 |
Cx-8998 |
- |
- |
- |
- |
1件: 6 |
345 |
Cyberknife |
- |
- |
- |
- |
1件: 6 |
346 |
Cymbalta |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 49 |
347 |
Cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
348 |
Cystoscopic injection of botox into the urinary bladder |
- |
- |
- |
- |
1件: 6 |
349 |
D-serine |
Serine |
D00016 |
- |
- |
1件: 6 |
350 |
D-serine (~2g/day) |
Serine |
D00016 |
- |
- |
1件: 6 |
351 |
Da-9701 |
- |
- |
- |
- |
1件: 6 |
352 |
Da-9805 45mg |
- |
- |
- |
- |
1件: 6 |
353 |
Da-9805 90mg |
- |
- |
- |
- |
1件: 6 |
354 |
Dacepton 5 mg/ml |
- |
- |
- |
- |
1件: 6 |
355 |
Dacepton 5 mg/ml infuusioneste, liuos |
- |
- |
- |
- |
1件: 6 |
356 |
Darifenacin |
Darifenacin |
D01699, D03654 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
2件: 6, 13 |
357 |
Dark chocolate (85% cocoa) |
Cocoa |
- |
- |
- |
1件: 6 |
358 |
Date |
Date |
- |
- |
- |
3件: 6, 88, 113 |
359 |
Datscan |
Ioflupane i-123 |
D10014 |
- |
- |
3件: 2, 5, 6 |
360 |
Datscan™ |
- |
- |
- |
- |
1件: 6 |
361 |
Dc158am |
- |
- |
- |
- |
1件: 6 |
362 |
Deanol |
Deanol |
D07777 |
- |
- |
1件: 6 |
363 |
Deanol pyroglutamate |
Deanol |
D07777 |
- |
- |
1件: 6 |
364 |
Debrumyl |
- |
- |
- |
- |
1件: 6 |
365 |
Deferiprone |
Deferiprone |
D07416 |
- |
- |
5件: 2, 6, 120, 122, 233 |
366 |
Deferiprone (ferriprox) |
Deferiprone |
D07416 |
- |
- |
1件: 6 |
367 |
Deferiprone 600 mg delayed release tablet |
Deferiprone |
D07416 |
- |
- |
1件: 6 |
368 |
Desmopressin |
Desmopressin |
D00291, D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
5件: 6, 64, 72, 225, 288 |
369 |
Desmopressin acetat |
Desmopressin |
D00291, D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
1件: 6 |
370 |
Desmotabs |
- |
- |
- |
- |
1件: 6 |
371 |
Desmotabs® 0,2 mg tabletten |
- |
- |
- |
- |
1件: 6 |
372 |
Desmotabs® 0,2mg tabletten |
- |
- |
- |
- |
1件: 6 |
373 |
Dexdor |
- |
- |
- |
- |
4件: 2, 4, 6, 70 |
374 |
Dexmedetomidina |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 6 |
375 |
Dexmedetomidine |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
11件: 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
376 |
Dexmedetomidine hydrochloride infusion |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 6 |
377 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
378 |
Different diets |
- |
- |
- |
- |
1件: 6 |
379 |
Dihydroergotoxine mesylate |
Ergoloid mesylate |
D02268 |
6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 6 |
380 |
Dipivefrin |
Dipivefrin |
D02349 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
381 |
Dipivefrine |
Dipivefrin |
D02349 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
382 |
Dipraglurant |
Dipraglurant |
- |
- |
- |
1件: 6 |
383 |
Ditropan elixir |
Oxybutynin |
D00465, D00722 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
384 |
Dm-1992 |
- |
- |
- |
- |
1件: 6 |
385 |
Dnl151 high dose |
- |
- |
- |
- |
1件: 6 |
386 |
Dnl151 low dose |
- |
- |
- |
- |
1件: 6 |
387 |
Dnl201 high dose |
- |
- |
- |
- |
1件: 6 |
388 |
Dnl201 low dose |
- |
- |
- |
- |
1件: 6 |
389 |
Dns-7801 (high dose) |
- |
- |
- |
- |
1件: 6 |
390 |
Dns-7801 (low-dose) |
- |
- |
- |
- |
1件: 6 |
391 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
392 |
Docosahexaenoic acid (dha) |
Doconexent |
- |
- |
- |
3件: 6, 94, 299 |
393 |
Domperidone |
Domperidone |
D01745, D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
5件: 6, 13, 17, 51, 230 |
394 |
Domperidone (drug) |
Domperidone |
D01745, D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
395 |
Dompéridone |
- |
- |
- |
- |
1件: 6 |
396 |
Donepezil |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
397 |
Donepezil sandoz |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
398 |
Dopamine |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 7, 74 |
399 |
Dopamine agent |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
400 |
Dopamine agonists (pramipexole, ropirinole) |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
401 |
Dopaminergic agonist + apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
402 |
Dopaminergic agonists |
- |
- |
- |
- |
1件: 6 |
403 |
Dops |
Droxidopa |
D01277 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 6, 17 |
404 |
Doxepin |
Doxepin |
D00814, D07875 |
3件: HRH1, SLC6A2, SLC6A4 |
5件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
1件: 6 |
405 |
Doxepin and zopiclone |
Zopiclone |
D01372 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
406 |
Dpa-714-pet/mri |
- |
- |
- |
- |
1件: 6 |
407 |
Droxidopa |
Droxidopa |
D01277 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 5, 6, 17 |
408 |
Duloxetine |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 6, 13 |
409 |
Duloxetine hydrochloride |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 6 |
410 |
Duodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
411 |
Duodopa intestinal gel |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
412 |
Duodopa ld/cd 20/5 mg/ml |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
413 |
Dynacirc cr (isradipine) |
Isradipine |
D00349 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
414 |
E2007 |
- |
- |
- |
- |
2件: 6, 144 |
415 |
Ebixa |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 6, 13 |
416 |
Ebixa® |
- |
- |
- |
- |
1件: 6 |
417 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
418 |
Elc200 |
- |
- |
- |
- |
1件: 6 |
419 |
Eliprodil |
Eliprodil |
- |
- |
- |
1件: 6 |
420 |
Eltoprazine |
Eltoprazine |
- |
- |
- |
1件: 6 |
421 |
Eltoprazine hcl |
Eltoprazine |
- |
- |
- |
1件: 6 |
422 |
Eltoprazine hydrochloride |
Eltoprazine |
- |
- |
- |
1件: 6 |
423 |
Emd 128130 |
- |
- |
- |
- |
2件: 6, 156 |
424 |
Emd128130 |
- |
- |
- |
- |
1件: 6 |
425 |
Ent-01 |
- |
- |
- |
- |
1件: 6 |
426 |
Entacapon |
- |
- |
- |
- |
1件: 6 |
427 |
Entacapona |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
428 |
Entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
2件: 6, 17 |
429 |
Entacapone and carbidopa |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
430 |
Epi-589 |
- |
- |
- |
- |
2件: 2, 6 |
431 |
Epi-743 200mg |
- |
- |
- |
- |
1件: 6 |
432 |
Epi-743 400mg |
- |
- |
- |
- |
1件: 6 |
433 |
Er cd-ld |
- |
- |
- |
- |
1件: 6 |
434 |
Er tablet 100 mg azd3241 |
- |
- |
- |
- |
1件: 6 |
435 |
Er tablet 25 mg azd3241 |
- |
- |
- |
- |
1件: 6 |
436 |
Eradication of helcobacter pylori |
- |
- |
- |
- |
1件: 6 |
437 |
Eradication therapy for h.pylori infection |
- |
- |
- |
- |
1件: 6 |
438 |
Eradication therapy for helicobacter pylori |
- |
- |
- |
- |
1件: 6 |
439 |
Erythromycin |
Erythromycin |
D00140, D00851, D01361, D02009, D02184, D02523, D02524, D02525, D04054 |
- |
- |
5件: 6, 36, 164, 228, 291 |
440 |
Erythropoietin |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
8件: 2, 6, 13, 22, 47, 70, 95, 96 |
441 |
Erythropoietin human recombinant (eporh) |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 6 |
442 |
Escitalopram |
Escitalopram |
D02567, D07704, D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 2, 6, 13 |
443 |
Esomeprazole |
Esomeprazole |
D01984, D04056, D07917, D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 6, 46, 86, 98, 298, 299 |
444 |
Eszopiclone |
Eszopiclone |
D02624 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 6, 13, 46 |
445 |
Ethnodyne visio |
- |
- |
- |
- |
1件: 6 |
446 |
Exametazime |
Exametazime |
D01109 |
- |
- |
1件: 6 |
447 |
Exelon |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 6, 13 |
448 |
Exelon 4.6 mg/24 h transdermal patch |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
449 |
Exelon 9.5 mg/24 h transdermal patch |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
450 |
Exelon patch (rivastigmine transdermal system) |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
451 |
Exenatide |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 6, 193, 233 |
452 |
Exenatide 10 micrograms |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
453 |
Exenatide 5 micrograms |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
454 |
F-18 fpcit |
- |
- |
- |
- |
1件: 6 |
455 |
Famotidine |
Famotidine |
D00318 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
3件: 6, 46, 86 |
456 |
Febuxostat |
Febuxostat |
D01206 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
3件: 2, 6, 13 |
457 |
Ferrprox (deferiprone) |
Deferiprone |
D07416 |
- |
- |
1件: 6 |
458 |
Fesoterodine |
Fesoterodine |
D07226 |
2件: CHRM2, CHRM3 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
459 |
Fetal porcine cells, neurocell-pd |
- |
- |
- |
- |
1件: 6 |
460 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
461 |
Finasteride |
Finasteride |
D00321 |
1件: SRD5A2 |
2件: Prostate cancer, Steroid hormone biosynthesis |
1件: 6 |
462 |
Fipamezole |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
463 |
Fipamezole hydrochloride |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
464 |
Fipamezole hydrochloride 30 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
465 |
Fipamezole hydrochloride 60 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
466 |
Fipamezole hydrochloride 90 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
467 |
Fipamezole odt |
Fipamezole |
- |
- |
- |
1件: 6 |
468 |
Fipamezole odt cohort 2 |
Fipamezole |
- |
- |
- |
1件: 6 |
469 |
Flecainide |
Flecainide |
D00638, D07962 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
470 |
Flecainide acetate |
Flecainide |
D00638, D07962 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
471 |
Flecainidum |
Flecainide |
D00638, D07962 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
472 |
Florbetaben (18f) |
- |
- |
- |
- |
1件: 6 |
473 |
Florbetapir f 18 |
- |
- |
- |
- |
1件: 6 |
474 |
Fludrocortisone |
Fludrocortisone |
D00986, D07967 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
3件: 6, 17, 81 |
475 |
Flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
5件: 6, 13, 17, 18, 206 |
476 |
Flutemetamol |
Flutemetamol |
- |
- |
- |
5件: 5, 6, 7, 17, 127 |
477 |
Folic acid |
Folic acid |
D00070 |
- |
- |
4件: 6, 46, 49, 84 |
478 |
Folic acid, vitamin b6, vitamin b12 |
Folic acid |
D00070 |
- |
- |
1件: 6 |
479 |
Foliglurax |
Foliglurax |
- |
- |
- |
1件: 6 |
480 |
Fpf1100nw |
- |
- |
- |
- |
1件: 6 |
481 |
Fpfs-1169 |
- |
- |
- |
- |
1件: 6 |
482 |
Fursultiamine |
Fursultiamine |
D03319 |
- |
- |
1件: 6 |
483 |
G-csf |
Filgrastim |
D03235 |
&nb |